The strategy of dual targeting TROP2-ADC and OXPHOS inhibitors can adopted to treat other cancers, besides ESCC, and it also includes AML, NSCLC, breast cancer, ovarian cancer, melanoma, etc. Therefore, this study provides an important foundation for future research into the therapeutic efficacy of TROP2 and OXPHOS combination in in other cancers. Here, TACSTD2 is linked to esophageal squamous cell carcinoma.